American Shared Hospital Services (AMS) Earnings Call Transcript & Summary

May 14, 2026

NYSE American US Health Care Health Care Providers and Services earnings 23 min

Earnings Call Speaker Segments

Kirin Smith

executive
#1

Thank you, operator, and I appreciate everyone joining us. AMS's earnings press release for the first quarter of 2026 was issued earlier today. If you'd like a copy, it's available in the Investors section of the company's website, www.ashs.com. Before I turn things over to management, I'd like to make a few comments about forward-looking statements. Please note that various things said on this conference call concerning the company's future expectations, plans, and prospects may qualify as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The outcomes we actually see could differ significantly from what those forward-looking statements suggest, due to a range of significant factors — among them the ones covered in the documents the company files with the SEC, such as our Form 10-Q covering the second quarter that closed on March 31st, 2026. Nothing obligates the company to revise whatever information this conference call contains. Prior to passing the microphone to management, I'd like to go over how we handle Q&A: every participant gets a chance for one question, plus a single follow-up. And naturally, we're glad to address any further questions after the call. So, let me now hand things over to our Executive Chairman, Ray Stachowiak. Go ahead, Ray.

Ray Stachowiak

executive
#2

Thanks, Kirin, and I'm glad everyone could join us today. First off, I want to bring you up to speed on changes within our leadership group, and then we'll go over a handful of key items from the quarter and explain further why we're feeling so excited and assured regarding our growth outlook. Near the end of April, we shared news of a leadership change: Gary Delanois has stepped away from his role as Chief Executive Officer for personal reasons, and the board has named Craig Tagawa to serve as interim CEO. We're grateful to Gary for everything he contributed, and we wish him well going forward. Craig's tenure with the company spans over 35 years, and it includes serving in leadership positions such as President, Chief Operating Officer, and Chief Financial Officer. He brings extensive experience in operations and finance, and having been part of this organization for so long, he's in a strong position to guide us into what comes next. Our confidence remains high that this team can keep pushing execution forward, grow treatment volumes, and bolster revenue growth. When we consider Q1 and how that carries over into Q2, the ongoing strides we're making throughout our network give us encouragement — especially when it comes to higher treatment volumes and better performance at the center level. I'm happy to share that positive volume trends are continuing as we move into our second quarter, and we're staying sharply focused on executing well. During the period, we achieved significant volume gains at the Orlando PBRT site, across our Rhode Island locations, and at our International Gamma Knife centers. Each of these made a direct contribution to the rise in revenue compared with the prior year, which mirrors the continued ramp-up occurring at these sites. Such developments matter because higher utilization serves as a major catalyst for top-line growth as well as margin improvement within our business model. Working alongside our partners stays at the heart of how we operate, and we keep collaborating closely with our health system allies to reinforce clinical offerings, foster physician alignment, and broaden patient reach for sophisticated radiation therapy services. Within Rhode Island, our joint efforts with prominent health systems keep enabling gains in staffing, referral trends, and broader operational performance. We think there's a lot of room to push volumes higher and get better financial results as those centers keep maturing. On the international side, Puebla is still growing nicely, and we're staying focused on keeping that momentum going while moving our wider global strategy forward. With both our LINAC and proton therapy platforms, demand trends look stable, and we feel our spending on this technology, along with the clinical capabilities, puts us in a good spot to capture that demand as time goes on. All in all, the gains we're seeing in volumes and revenue, we believe, show how strong our model is and reflect the base we've established over the last several years through our partnerships and investments. Turning to what's coming up, there's a lot of potential we see overseas, and that includes building out our Guadalajara center, which should start up in the later part of this year. Meanwhile, in Rhode Island, the road to growth is now clear-cut, since we got Certificate of Need approvals for a new radiation therapy site in Bristol and a Proton Beam Radiation Therapy Center in Johnston. These projects are key engines for growth over the long haul and deepen our ties with leading health systems throughout the region. My confidence in this company's potential for growth remains high, and I firmly hold the view that today's valuation fails to capture what our core business is truly worth or the possibilities that lie ahead for us. At this point, I'll turn things over to Craig Tagawa, who serves as our President and Interim Chief Executive Officer.

Craig Tagawa

executive
#3

Thanks, Ray. Hello, everyone. It's an honor to take on the Interim Chief Executive Officer position at such a pivotal moment for this company. I've spent more than 34 years with this organization, so I've witnessed directly how strong our partnerships are, how committed our team is, and how our business has evolved. My commitment is to keep our strategy consistent while staying sharply focused on execution, operational discipline, and creating long-term value for shareholders. We feel good about how we performed in Q1 of 2026, which shows ongoing momentum within our Direct Patient Care Services segment along with better utilization at our treatment centers. Revenue rose roughly 15.9% compared with the same period last year, reaching $7.1 million, fueled by significant contributions from our radiation therapy centers in Rhode Island and Puebla, plus expansion in Proton Therapy volumes. Crucially, this improvement came alongside higher patient volumes throughout the network, something we see as a crucial sign of stronger demand and better operational execution. I'm happy to share as well that adjusted EBITDA for the quarter grew 18.4% versus the prior-year period. Throughout the quarter, we kept making headway ramping up our centers, especially in Rhode Island, where we've focused on stabilizing physician staffing and strengthening clinical operations; those efforts are producing greater treatment volumes and steadier performance platform-wide. Our Puebla center likewise kept delivering solid results, helped by better reimbursement dynamics and continued operational ramp-up, and we consider it a key driver of both present results and future expansion. Strategically, we remain concentrated on growing and optimizing organic growth at every one of our sites. That means raising utilization at centers we already operate, enhancing revenue cycle performance, and further building up our clinical capabilities and patient access. We're additionally experiencing early gains from operational initiatives rolled out during the last year, such as better aligning our cost structure with the size of our business and improving coordination among our centers. There's still more to accomplish, but we think the strides we're making in volumes, revenue, and operating performance demonstrate that we're headed in the right direction and starting to capture the advantages of our work. With that, I'll hand the call over to Scott.

Scott Frech

executive
#4

Thanks, Craig, and hi everybody. In the first quarter of 2026, our total revenue climbed 15.9% to $7.1 million, compared with $6.1 million across the same stretch 12 months before. Driving most of that increase was our direct patient care services segment, which generated about $4.1 million — a 30.2% increase over $3.1 million in the matching prior-year span. That growth reflects higher procedure volumes at our sites in Rhode Island and at our radiation therapy center in Puebla, Mexico, since those facilities continue to lift utilization and move more patients through. Leasing revenue was approximately $3 million, basically level with the same period last year. Even though procedure volumes increased in certain areas, those improvements were largely offset by a Gamma Knife customer contract that expired in April 2025. By modality, we saw robust growth in proton beam radiation therapy, where revenue benefited from heavier volumes and total fractions increased over 20% compared with a year ago. Gamma Knife revenue also increased, driven by momentum in our Direct Patient Services segment, particularly at international sites in Peru and Ecuador, where volumes benefited from equipment upgrades and improved operating conditions. On profitability, gross margin improved about 36.7% from the prior year to $1.3 million, or 18.2%, compared to $0.9 million, or 15.4%, in the prior year period — a gain of roughly 44% over the prior year, fueled by higher overall revenue and better utilization across our treatment network, which more than offset the steeper cost structure tied to our expanding Direct Patient Services segment. Total cost of revenue rose to $5.8 million from $5.2 million in the prior-year period, mainly because of greater operating costs associated with our direct patient services model. That included additional staffing, facility-related expenses, and maintenance costs at our Rhode Island and Puebla locations. We also incurred higher maintenance expenses as certain LINAC systems fell out of warranty, and maintenance contract costs for our PBRT in Orlando kept climbing. Those increases were partly offset by reduced depreciation and amortization expense, reflecting contract expirations and certain assets reaching full depreciation. Selling and administrative expenses edged up modestly to $1.9 million, mostly from higher audit, tax, and consulting fees, partly offset by lower legal expenses. Operating performance improved to a loss of $0.9 million, compared with a loss of $1.3 million in the prior-year period, reflecting the benefit of revenue growth and margin expansion, partly offset by the continued ramp-up at newer facilities that carry higher fixed costs near term. Net loss attributable to the company improved to $0.6 million, or $0.09 per diluted share, against $0.10 per diluted share in the prior-year period. While we still report a net loss, that reflects ongoing investment in our Direct Patient Services segment, and we expect better results as utilization keeps scaling. Importantly, I'm happy to report that adjusted EBITDA climbed 18.4% to $1.1 million, compared with $949,000 during the same period last year. Turning to the balance sheet, at the end of the quarter we had about $5.2 million in cash equivalents and restricted cash, compared with $3.7 million at year-end. That improvement reflects stronger operating results as well as working capital timing. On March 31, 2026, the current portion of our long-term debt came to $16.8 million, lower than the $17.3 million recorded on December 31, 2025. We continue to actively manage our capital structure while supporting growth of our operating platform, and discussions with our lender regarding a potential extension are still constructive. Gross margin rose roughly 36.7% versus the prior year, reaching $1.3 million, or 18.2%, up from $0.9 million, or 15.4%, in the same period a year earlier. Overall, the stronger operating performance encourages us, and we remain focused on increasing revenue, expanding margins, and enhancing financial flexibility. With that, operator, we're ready for questions.

M. Marin

analyst
#5

Thanks. I'd like you to refresh our memory, if you would, and let us know as well if you believe things are still tracking toward the debut of that new site you've mentioned before — the one you brought up a bit earlier during your prepared comments — the new site located in Rhode Island?

Ray Stachowiak

executive
#6

Sure, I appreciate the question; those 2 centers remain on schedule. Bear in mind that projects like these take a long time. Our 4th center in the state would be the radiation therapy center in Bristol, Rhode Island. The eastern part of the state, where it sits, is underserved. We don't anticipate that site opening for another 18 or 24 months. Further off still is the proton beam facility in Johnston, Rhode Island. That one is roughly 24 to 30 months away.

M. Marin

analyst
#7

Okay, thank you. I believe I have a single follow-up question. You said the first quarter's numbers aren't truly comparable on a like-for-like basis due to a contract that lapsed last year. The anniversary of that is nearly here. Going forward, should we anticipate greater comparability in the year-over-year figures?

Ray Stachowiak

executive
#8

I think that despite that agreement ending, and therefore the volume treatment count was part of first quarter 2025 for comparison reasons, and we managed to keep treatment volume stable year-over-year in spite of that termination. I think the outlook would be a year-over-year gain in that segment.

M. Marin

analyst
#9

Let me slip in a final question here. I realize it's, well.

Ray Stachowiak

executive
#10

All right.

M. Marin

analyst
#11

Alright, I'll rejoin the line later. Thanks. Could you say that highlights certain advantages of your direct patient approach, allowing you to exercise more authority over some of those revenue sources you're considering?

Ray Stachowiak

executive
#12

Yes. Our Direct Patient Services segment keeps expanding quite strongly, as we see it. We feel our firm and its operating model have shifted in the direction of that segment. At the same time, we still hold onto the revenue sources from our leasing segment, and, you know, during this quarter, that leasing segment was, I believe, unchanged, while Direct Patient Services delivered our growth.

M. Marin

analyst
#13

Thank you.

Tony Keenan

analyst
#14

Yes. Hello. It's good to see a bit of progress this quarter. Craig, it's wonderful to have you in a role of even greater significance. I'm aware of how many years you've spent at the company, so that's really nice to see. I've got one question plus a follow-up. The first one is simply for a bit of clarity. A report from Zacks back in April stated, and I'm quoting here, "Benefits could be partially offset by a contract that the company expects to expire in Q2 2026." Could you say a little about that? Ray, as you just mentioned, it seems like treatment volumes are solid and we've begun to see the effects getting better. Is that contract being referenced, the one that might expire, going to be something truly material, or do you have any thoughts on it?

Ray Stachowiak

executive
#15

No, my view is it won't produce any material impact, since we signed a 2-year extension on that agreement, so revenue from that site will keep flowing.

Tony Keenan

analyst
#16

All right, that sounds good. So for my follow-up, I've got a remark plus a question. Initially, when you fell out of compliance with the bank, it had to do with the cash balance sitting below $5 million. I can see you've climbed back above $5 million now. I'm aware there were a couple of other things you needed to remedy there — fixed charges, and I believe an EBITDA ratio as well. Now that you're over the threshold on cash, and given that quite a bit of time has passed, could you share any perspective on how much longer you anticipate that process with the bank will run? You've said a few times that you have some positive feelings about the direction it's heading, but any additional detail would be welcome.

Scott Frech

executive
#17

Yeah, Tony, that's a good question. Regarding our talks with our banking relationship at Fifth Third Bank, I'd describe them as ongoing and, you know, progressing well. Past that, I'm not in a position to comment on those discussions, but what I can do is, I'll say, verify our cash balance as of 12/31 — I believe we had $3.7 million in cash — and as of 3/31, our cash balance has grown to more than $5 million. Bear in mind that out of that $5 million, a portion sits within our international operations, and we've lately managed to repatriate some of those funds back into the United States.

Tony Keenan

analyst
#18

Alright.

Scott Frech

executive
#19

So, when you look at it, our cash balances have gone up.

Tony Keenan

analyst
#20

Great. Thank you.

Craig Tagawa

executive
#21

Thank you. As we wrap up, the first quarter brought results we're happy about — especially gains in our direct patient services segment and better operating performance. The things we're focused on haven't changed: getting more utilization out of each of our centers, making operations more efficient, and putting our finances on stronger footing. The groundwork we've laid, we believe, sets us up nicely for continued progress in 2026. Thanks to everyone for being here today, and we're eager to keep you informed as we move forward. If any other questions come up in the meantime, don't hesitate to get in touch. On that note, enjoy the remainder of your day.

Operator

operator
#22

That brings today's presentation to a close. We appreciate you joining us, and you're free to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.